929(top 1%)
papers
58.0K(top 0.1%)
citations
103(top 0.1%)
h-index
219(top 0.1%)
g-index
981
all documents
62.1K
doc citations
4.4K
citing journals

Top Articles

#TitleJournalYearCitations
1Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine20097,606
2MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience20074,187
3ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology20162,545
4Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet Oncology, The20181,816
5Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology20181,571
6Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabNature Medicine2018936
7Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialLancet Oncology, The2017877
8Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialLancet Respiratory Medicine,the2019704
9Non-small-cell lung cancerNature Reviews Disease Primers2015653
10Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology2017653
11Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessmentsProceedings of the National Academy of Sciences of the United States of America2015579
12Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology2009576
13Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2015574
14A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJournal of the National Cancer Institute2005567
15Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging systemCancer2002551
16Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel SequencingClinical Chemistry2013447
17Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung CarcinomaJAMA Oncology2018437
18Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trialLancet, The1999436
19Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialAnnals of Oncology2017425
20Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastographyGut2012423
21Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal CarcinomaJournal of the National Cancer Institute2002384
22Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncology, The2015353
23Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal CarcinomaJournal of Clinical Oncology2006346
24Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus1999341
25Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerNature Medicine2020322
26Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinomaJournal of Hepatology2020310
27Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumorsInternational Journal of Radiation Oncology Biology Physics1995297
28Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalationInternational Journal of Radiation Oncology Biology Physics2003279
29Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging1996278
30High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular CarcinomaJournal of Clinical Oncology2008278
31FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancerMolecular Cancer2017276
32Assessment of Genetic Changes in Hepatocellular Carcinoma by Comparative Genomic Hybridization AnalysisAmerican Journal of Pathology1999274
33Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developmentsExpert Reviews in Molecular Medicine2007266
34Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal StudyPLoS ONE2013266
35Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialJournal of Thoracic Oncology2019260
36Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic ChemotherapyJournal of Clinical Oncology2004255
37Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept studyAnnals of Hepatology2013252
38Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylationOncogene2006247
39Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerAnnals of Oncology2014246
40Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyAnnals of Oncology2018243
41Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance SpectroscopyAmerican Journal of Gastroenterology2015240
42Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialLancet Oncology, The2022237
43Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Journal of Clinical Oncology2022235
44Scientific Advances in Lung Cancer 2015Journal of Thoracic Oncology2016231
45Overview of current systemic management of EGFR-mutant NSCLCAnnals of Oncology2018229
46Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its SubtypesClinical Chemistry2003228
47Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutationsNature Communications2017227
48Systemic treatment of hepatocellular carcinoma: An EASL position paperJournal of Hepatology2021217
49Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinomaClinical Cancer Research1999216
50Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancerEuropean Journal of Nuclear Medicine and Molecular Imaging1997206